Figure 4
JZL184 reduces CA1 presynaptic GABA release (a–e) Histogram (left) and representative traces (right) show that relative to control (Con), a JZL184 injection (J 20: 20 mg kg−1, intraperitoneal (i.p.)), but not vehicle (Veh), decreases miniature inhibitory postsynaptic current (mIPSC) frequency (a) and increases paired pulse facilitation (PPF) ratio of inhibitory postsynaptic current (IPSC) (d), which are abolished by AM281 pretreatment (b, e), without significant effects on mIPSC amplitude (c). (f) JZL184 significantly decreases the magnitude (P<0.05) of depolarization-induced suppression of inhibition (DSI) that is induced by 5-s depolarization from −70 to 0 mV. Representative IPSC traces are superimposed on the top. (g, h) Histograms show that JZL184 does not significantly affect miniature excitatory postsynaptic current (mEPSC) frequency (g) or amplitude (h). (i) JZL184 does not significantly affect the magnitude (P=0.17) of depolarization-induced suppression of excitation (DSE), which is induced by 5-s depolarization from −70 to 0 mV. Representative excitatory postsynaptic current (EPSC) traces are superimposed on the top. *P<0.05 and **P<0.01 vs control, LSD post-hoc test after one-way ANOVA (a: F2,13=6.181, P<0.05; b: F2,12=0.278, P=0.762; c: F2,13=0.207, P=0.816; d: F2,14=10.91, P<0.01; e: F2,13=0.034, P=0.967) or t test (f–i).
